These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

876 related items for PubMed ID: 30270071

  • 1. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Vrablik M, Raslová K, Vohnout B, Blaha V, Satny M, Kyselak O, Vaclova M, Urbanek R, Maskova J, Soska V, Freiberger T.
    Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
    Vohnout B, Fábryová Ľ, Klabník A, Kadurová M, Bálinth K, Kozárová M, Bugáňová I, Sirotiaková J, Rašlová K.
    Atherosclerosis; 2018 Oct; 277():323-326. PubMed ID: 30270066
    [Abstract] [Full Text] [Related]

  • 4. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S, Boccara F, Cariou B, Carrié A, Collet X, Farnier M, Ferrières J, Krempf M, Peretti N, Rabès JP, Varret M, Vimont A, Charrière S, Bruckert E, French FH Registry group.
    Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH, Santos RD.
    Prog Cardiovasc Dis; 2019 Oct; 62(5):414-422. PubMed ID: 31669498
    [Abstract] [Full Text] [Related]

  • 7. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P, SAFEHEART Investigators.
    J Am Coll Cardiol; 2016 Mar 22; 67(11):1278-85. PubMed ID: 26988947
    [Abstract] [Full Text] [Related]

  • 8. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ, Hovingh GK, Catapano AL.
    Atherosclerosis; 2018 Oct 22; 277():483-492. PubMed ID: 30270089
    [Abstract] [Full Text] [Related]

  • 9. Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.
    Brunham LR, Ruel I, Khoury E, Hegele RA, Couture P, Bergeron J, Baass A, Dufour R, Francis GA, Cermakova L, Mancini GBJ, Brophy JM, Brisson D, Gaudet D, Genest J.
    Atherosclerosis; 2018 Oct 22; 277():419-424. PubMed ID: 30270080
    [Abstract] [Full Text] [Related]

  • 10. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V, Katsiki N, Makrygiannis S, Mavrogieni S, Karampetsou N, Manolis A, Melidonis A, Mikhailidis DP, Kolovou GD.
    J Cardiovasc Pharmacol Ther; 2021 Jan 22; 26(1):51-58. PubMed ID: 32729335
    [Abstract] [Full Text] [Related]

  • 11. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L, Plana N, Pérez-Calahorra S, Ibarretxe D, Lamiquiz-Moneo I, Pedro-Botet J, Suárez-Tembra M, Valdivielso P, Ortega E, Civeira F, Dyslipidemia Registry of the Spanish Arteriosclerosis Society.
    Atherosclerosis; 2017 Jul 22; 262():107-112. PubMed ID: 28531826
    [Abstract] [Full Text] [Related]

  • 12. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA.
    Circulation; 2012 Nov 13; 126(20):2408-17. PubMed ID: 23129602
    [Abstract] [Full Text] [Related]

  • 13. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F, Dal Pino B, Bigazzi F, Ripoli A, Passino C, Gabutti A, Pasanisi EM, Petersen C, Valleggi A, Todiere G, Barison A, Giannoni A, Panchetti L, Becherini F, Pianelli M, Luciani R, Sampietro T.
    Eur J Prev Cardiol; 2017 Sep 13; 24(14):1528-1531. PubMed ID: 28555526
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B, Bourane S, Tang L, Farnier M, Raal FJ, Lambert G.
    Arterioscler Thromb Vasc Biol; 2018 Mar 13; 38(3):592-598. PubMed ID: 29284604
    [Abstract] [Full Text] [Related]

  • 17. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
    Blom DJ, Ranjith N, Joshi P, Naidoo P, van Tonder A, Musa MG, Joshi S, Leisegang R, Trokis JS, Makan H, Raal FJ.
    Cardiovasc J Afr; 2020 Mar 13; 31(5):245-251. PubMed ID: 33151240
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag.
    Baum SJ, Brown AS.
    Rev Cardiovasc Med; 2018 Mar 13; 19(S1):S25-S30. PubMed ID: 30207555
    [Abstract] [Full Text] [Related]

  • 20. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M.
    Atherosclerosis; 2017 Jan 13; 256():134-145. PubMed ID: 27993383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.